Table of Content

Executive Summary
1 Product Definition

2 Scope of the Work
2.1 Overview: Report Scope
2.2 Segmentation of the Global Viral Vector and Plasmid Manufacturing Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in the Report
2.5 Base Year and Forecast Period

3 Research Methodology
3.1 Overview: Report Methodology

4 Global Viral Vector and Plasmid Manufacturing Market Overview
4.1 Market Overview
4.2 Introduction to Vectors
4.3 Importance of Viral Vectors and Plasmid DNA
4.4 Major Milestone in Vector Manufacturing
4.4.1 Manufacturing Process
4.4.1.1 Upstream Bioprocessing
4.4.1.2 Downstream Bioprocessing
4.5 Global Viral Vector and Plasmid Manufacturing Market Size, 2019-2030

5 Market Dynamics
5.1 Market Drivers
5.1.1 Rapid Uptake of Viral Vectors and Plasmid for the Development of Innovative Therapies
5.1.2 Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases
5.1.3 Increasing Number of Clinical Studies for the Development of Gene Therapy
5.1.4 Favorable Funding Scenario for Vector-Based Therapies
5.2 Market Restraints
5.2.1 Unaffordable Cost of Gene Therapies
5.2.2 High Manufacturing Costs of Viral Vectors and Plasmids
5.2.3 Complications Associated With Large-Scale Production of Vectors
5.3 Market Opportunities
5.3.1 Rising Demand for Synthetic Genes
5.3.2 Emergence of Next-Generation Vectors

6 Industry Insights
6.1 Overview
6.2 Regulatory Scenario
6.3 Patent Landscape

7 Competitive Landscape
7.1 Overview
7.2 Key Developments and Strategies
7.2.1 Partnerships and Alliances
7.2.2 Business Expansions
7.2.3 New Offerings
7.2.4 M & A Activities
7.2.5 Others
7.3 Market Share Analysis

8 Global Viral Vector and Plasmid Manufacturing Market (by Vector)
8.1 Overview
8.2 Viral Vector
8.2.1 Adenoviral Vector
8.2.2 Retroviral Vector
8.2.3 Adeno-Associated Viral Vector
8.2.4 Lentiviral Vector
8.2.5 Vaccinia Viral Vector
8.2.6 Other Viral Vectors
8.3 Plasmid

9 Global Viral Vector and Plasmid Manufacturing Market (by Disease)
9.1 Overview
9.2 Cancer
9.3 Genetic Disease
9.4 Infectious Disease
9.5 Cardiovascular Disease
9.6 Other Diseases

10 Global Viral Vector and Plasmid Manufacturing Market (by Application)
10.1 Overview
10.2 Gene Therapy
10.3 Vaccinology
10.4 Cell Therapy
10.5 Other Applications

11 Global Viral Vector and Plasmid Manufacturing Market (by Region)
11.1 Overview
11.2 North America
11.2.1 Overview
11.2.2 U.S.
11.2.3 Canada
11.3 Europe
11.3.1 Overview
11.3.2 Germany
11.3.3 U.K.
11.3.4 France
11.3.5 Italy
11.3.6 Switzerland
11.3.7 Belgium
11.3.8 Spain
11.3.9 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 Overview
11.4.2 China
11.4.3 Australia
11.4.4 Japan
11.4.5 India
11.4.6 South Korea
11.4.7 Singapore
11.4.8 Rest-of-Asia-Pacific
11.5 Rest-of-the-World
11.5.1 Overview

12 Company Profiles
12.1 Overview
12.2 Aldevron, LLC
12.2.1 Company Overview
12.2.2 Role of Aldevron, LLC in the Global Viral Vector and Plasmid Manufacturing Market
12.2.3 SWOT Analysis
12.3 Boehringer Ingelheim
12.3.1 Company Overview
12.3.2 Role of Boehringer Ingelheim in the Global Viral Vector and Plasmid Manufacturing Market
12.3.3 SWOT Analysis
12.4 Catalent, Inc.
12.4.1 Company Overview
12.4.2 Role of Catalent, Inc. in the Global Viral Vector and Plasmid Manufacturing Market
12.4.3 Financials
12.4.4 Key Insights About Financial Health of the Company
12.4.5 SWOT Analysis
12.5 FUJIFILM Holdings Corporation
12.5.1 Company Overview
12.5.2 Role of FUJIFILM Holdings Corporation in the Global Viral Vector and Plasmid Manufacturing Market
12.5.3 Financials
12.5.4 Key Insights About Financial Health of the Company
12.5.5 SWOT Analysis
12.6 GENERAL ELECTRIC
12.6.1 Company Overview
12.6.2 Role of GENERAL ELECTRIC in the Global Viral Vector and Plasmid Manufacturing Market
12.6.3 Financials
12.6.4 Key Insights About Financial Health of the Company
12.6.5 SWOT Analysis
12.7 GenScript
12.7.1 Company Overview
12.7.2 Role of GenScript in the Global Viral Vector and Plasmid Manufacturing Market
12.7.3 Financials
12.7.4 Key Insights About Financial Health of the Company
12.7.5 SWOT Analysis
12.8 Lonza
12.8.1 Company Overview
12.8.2 Role of Lonza in the Global Viral Vector and Plasmid Manufacturing Market
12.8.3 Financials
12.8.4 Key Insights About Financial Health of the Company
12.8.5 SWOT Analysis
12.9 Merck KGaA
12.9.1 Company Overview
12.9.2 Role of Merck KGaA in the Global Viral Vector and Plasmid Market
12.9.3 Financials
12.9.4 Key Insights About Financial Health of the Company
12.9.5 SWOT Analysis
12.10 MolMed S.p.A.
12.10.1 Company Overview
12.10.2 Role of MolMed S.p.A. in the Global Viral Vector and Plasmid Manufacturing Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Novasep Holding SAS
12.11.1 Company Overview
12.11.2 Role of Novasep Holding SAS in the Global Viral Vector and Plasmid Manufacturing Market
12.11.3 SWOT Analysis
12.12 Oxford Biomedica plc
12.12.1 Company Overview
12.12.2 Role of Oxford Biomedica plc in the Global Viral Vector and Plasmid Manufacturing Market
12.12.3 Financials
12.12.4 Key Insights About Financial Health of the Company
12.12.5 SWOT Analysis
12.13 Sartorius AG
12.13.1 Company Overview
12.13.2 Role of Sartorius AG in the Global Viral Vector and Plasmid Manufacturing Market
12.13.3 Financials
12.13.4 Key Insights About Financial Health of the Company
12.13.5 SWOT Analysis
12.14 Takara Bio Inc.
12.14.1 Company Overview
12.14.2 Role of Takara Bio Inc. in the Global Viral Vector and Plasmid Manufacturing Market
12.14.3 Financials
12.14.4 Key Insights About Financial Health of the Company
12.14.5 SWOT Analysis
12.15 Thermo Fisher Scientific Inc.
12.15.1 Company Overview
12.15.2 Role of Thermo Fisher Scientific Inc. in the Global Viral Vector and Plasmid Manufacturing Market
12.15.3 Financials
12.15.4 Key Insights About Financial Health of the Company
12.15.5 SWOT Analysis
12.16 WuXi AppTec
12.16.1 Company Overview
12.16.2 Role of WuXi AppTec in the Global Viral Vector and Plasmid Manufacturing Market
12.16.3 Financials
12.16.4 Key Insights About Financial Health of the Company
12.16.5 SWOT Analysis: WuXi AppTec

List of Tables

Table 1: Leading Segments of the Global Viral Vector and Plasmid Manufacturing Market, 2019 and 2030
Table 4.1: Advantages and Disadvantages of Common Viral Vectors and Plasmids
Table 5.1: Gene Therapy for Different Types of Cancer
Table 5.2: Recent Approvals for Gene Therapy
Table 5.3: Companies Offering Gene Therapies and Their Cost
Table 6.1: Global Regulatory Scenario
Table 6.2: Patents Related to Viral Vectors and Plasmids (January 2017-February 2020)
Table 8.1: Examples of Viral Vectors Used in Gene Therapy
Table 8.2: Plasmids Used in Gene Therapy Trials
Table 9.1: Examples of Ad Vectors for Cancer Gene Therapy
Table 9.2: Features of Vectors Used in Cardiovascular Therapy
Table 10.1: Examples of Clinical Trials Using Viral Vectors
Table 10.2: Advantages and Disadvantages Associated with Major Viral Vectors
Table 11.1: Examples of Key Companies with Headquarters in the U.S.

List of Figures

Figure 1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030
Figure 2: Key Players of the Global Viral Vector and Plasmid Manufacturing Market
Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market
Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
Figure 5: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030
Figure 6: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030
Figure 7: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030
Figure 8: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030
Figure 2.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation
Figure 3.1: Global Viral Vector and Plasmid Manufacturing Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 4.1: Mechanism of Action of Vectors
Figure 4.2: Evolutionary History of Vectors
Figure 4.3: Typical Production Methods of Viral Vectors and Plasmids
Figure 4.4: Global Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 5.1: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market
Figure 5.2: Estimated New Cancer Cases and Deaths (by Sex), U.S., 2020
Figure 6.1: Workflow Associated With Biomanufacturing
Figure 6.2: Global Viral Vector and Plasmid Manufacturing Market: Patent Analysis (by Year of Publication), June 2017-December 2019
Figure 7.1: Competitive Landscape, January 2017- March 2020
Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
Figure 7.4: Business Expansions (by Company), January 2017-February 2020
Figure 7.5: New Offerings (by Company), January 2017-February 2020
Figure 7.6: M&A Activities (by Company), January 2017-February 2020
Figure 7.7: Others (by Company), January 2017-February 2020
Figure 7.8: Market Share Analysis of Global Viral Vector and Plasmid Manufacturing Market, 2019
Figure 8.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Vector)
Figure 8.2: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030
Figure 8.3: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030
Figure 8.4: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030
Figure 8.5: Global Viral Vector and Plasmid Manufacturing Market for Adenoviral Vectors, 2019-2030
Figure 8.6: Global Viral Vector and Plasmid Manufacturing Market for Retroviral Vectors, 2019-2030
Figure 8.7: Global Viral Vector and Plasmid Manufacturing Market for Adeno-Associated Viral Vectors, 2019-2030
Figure 8.8: Global Viral Vector and Plasmid Manufacturing Market for Lentiviral Vectors, 2019-2030
Figure 8.9: Global Viral Vector and Plasmid Manufacturing Market for Vaccinia Viral Vectors, 2019-2030
Figure 8.10: Global Viral Vector and Plasmid Manufacturing Market for Other Viral Vectors, 2019-2030
Figure 8.11: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030
Figure 9.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Disease)
Figure 9.2: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030
Figure 9.3: Global Viral Vector and Plasmid Manufacturing Market for Cancer, 2019-2030
Figure 9.4: List of Monogenic Disorders for which Human Gene Transfer Trials Have Been Approved
Figure 9.5: Global Viral Vector and Plasmid Manufacturing Market for Genetic Diseases, 2019-2030
Figure 9.6: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030
Figure 9.7: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030
Figure 9.8: Global Viral Vector and Plasmid Manufacturing Market for Other Diseases, 2019-2030
Figure 10.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Application)
Figure 10.2: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030
Figure 10.3: Global Viral Vector and Plasmid Manufacturing Market for Gene Therapy, 2019-2030
Figure 10.4: Global Viral Vector and Plasmid Manufacturing Market for Vaccinology, 2019-2030
Figure 10.5: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030
Figure 10.6: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030
Figure 11.1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030
Figure 11.2: North America: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.5: U.S.: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.6: Canada: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.7: Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.10: Germany: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.11: U.K.: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.12: France: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.13: Italy: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.14: Switzerland: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.15: Belgium: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.16: Spain: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.17: Rest-of-Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.18: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.19: Asia-Pacific: Market Dynamics
Figure 11.20: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030
Figure 11.21: China: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.22: Australia: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.23: Japan: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.24: India: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.25: South Korea: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.26: Singapore: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.27: Rest-of-Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.28: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market, 2019-2030
Figure 11.29: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market (Latin America and Middle-East and Africa), 2019-2030
Figure 12.1: Shares of Key Company Profiles
Figure 12.2: Aldevron, LLC: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.3: Aldevron, LLC: SWOT Analysis
Figure 12.4: Boehringer Ingelheim: Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.5: Boehringer Ingelheim: SWOT Analysis
Figure 12.6: Catalent, Inc: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.7: Catalent, Inc: Overall Financials, 2017-2019
Figure 12.8: Catalent, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.9: Catalent, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.10: Catalent, Inc.: R&D Expense, 2017-2019
Figure 12.11: Catalent, Inc.: SWOT Analysis
Figure 12.12: FUJIFILM Holdings Corporation: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.13: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
Figure 12.14: FUJIFILM Holdings Corporation: Net Revenue (by Business Segment), 2017-2019
Figure 12.15: FUJIFILM Holdings Corporation: Healthcare and Material Solutions Revenue (by Sub-Segment), 2017-2019
Figure 12.16: FUJIFILM Holdings Corporation: R&D Expense, 2017-2019
Figure 12.17: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 12.18: GE Healthcare: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.19: GENERAL ELECTRIC Company: Overall Financials, 2017-2019
Figure 12.20: GENERAL ELECTERIC: Revenue (by Business Model), 2017-2019
Figure 12.21: GENERAL ELECTRIC: Revenue (by Region), 2017-2019
Figure 12.22: GENERAL ELECTRIC: R&D Expenditure, 2017-2019
Figure 12.23: GENERAL ELECTRIC: SWOT Analysis
Figure 12.24: GenScript: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.25: GenScript: Overall Financials, 2016-2018
Figure 12.26: GenScript: R&D Expense, 2016-2018
Figure 12.27: GenScript: SWOT Analysis
Figure 12.28: Lonza: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.29: Lonza: Overall Financials, 2017-2019
Figure 12.30: Lonza: Revenue (by Segment), 2017-2019
Figure 12.31: Lonza: Revenue (by Region), 2017-2019
Figure 12.32: Lonza: R&D Expenditure (2017-2019)
Figure 12.33: Lonza: SWOT Analysis
Figure 12.35: Merck KGaA: Overall Financials, 2017-2019
Figure 12.36: Merck KGaA: Revenue (by Product and Services), 2017-2019
Figure 12.37: Merck KGaA: Revenue (by Region), 2017-2019
Figure 12.38: Merck KGaA: R&D Expenditure, 2017-2019
Figure 12.40: MolMed S.p.A.: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.41: MolMed S.p.A.: Overall Financials, 2016-2018
Figure 12.42: MolMed S.p.A.: SWOT Analysis
Figure 12.43: Novasep Holding SAS: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.44: Novasep Holding SAS: SWOT Analysis
Figure 12.45: Oxford Biomedica plc: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market
Figure 12.46: Oxford Biomedica plc: Overall Financials, 2016-2018
Figure 12.47: Oxford Biomedica plc: Revenue (by Segment), 2016-2018
Figure 12.48: Oxford Biomedica plc: R&D Expenditure (2016-2018)
Figure 12.49: Oxford Biomedica plc: SWOT Analysis
Figure 12.50: Sartorius AG: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.51: Sartorius AG: Overall Financials, 2017-2019
Figure 12.52: Sartorius AG: Revenue (by Business Segment), 2017-2019
Figure 12.53: Sartorius AG: Revenue (by Region), 2017-2019
Figure 12.54: Sartorius AG: R&D Expenditure (2017-2019)
Figure 12.55: Sartorius AG: SWOT Analysis
Figure 12.56: Takara Bio Inc.: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.57: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 12.58: Takara Bio Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.59: Takara Bio Inc.: Revenue (by Region), 2017-2019
Figure 12.60: Takara Bio Inc.: R&D Expenditure (2017-2019)
Figure 12.61: Takara Bio Inc.: SWOT Analysis
Figure 12.62: Thermo Fisher Scientific, Inc.: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.63: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 12.64: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.65: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2017-2019
Figure 12.66: Thermo Fisher Scientific, Inc.: R&D Expenditure (2017-2019)
Figure 12.67: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 12.68: WuXi AppTec: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market
Figure 12.69: WuXi AppTec: Overall Financials, 2016-2018
Figure 12.70: WuXi AppTec: Net Revenue (by Business Segment), 2016-2018
Figure 12.71: WuXi AppTec: Net Revenue (by Region), 2016-2018
Figure 12.72: WuXi AppTec: R&D Expense, 2016-2018
Figure 12.73: WuXi AppTec: SWOT Analysis